Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Globus Medical (GMED)

Globus Medical Q4 sales rise 6.6% to $657.3 million; GAAP EPS $0.19 vs $0.11

Positive Impact 3 of 5 earnings Written later

Globus Medical reported fourth-quarter 2024 net sales of $657.3 million, up 6.6% from a year earlier, and GAAP net income of $26.5 million, up from $15.0 million. For the full year, sales were $2.52 billion, up 60.6%, largely from the NuVasive merger, but GAAP net income fell to $103.0 million from $122.9 million. The company reaffirmed its stand-alone 2025 guidance and gave new guidance that includes the pending Nevro acquisition.

Key points

  • Q4 2024 GAAP diluted EPS was $0.19 versus $0.11; non-GAAP diluted EPS was $0.84 versus $0.60
  • Full-year 2024 GAAP diluted EPS was $0.75 versus $1.07 in 2023; non-GAAP diluted EPS was $3.04
  • Stand-alone 2025 revenue guidance of $2.66 billion to $2.69 billion reaffirmed; non-GAAP EPS guidance of $3.40 to $3.50
  • With Nevro acquisition, expected to close in late second quarter 2025, 2025 net sales guidance is $2.80 billion to $2.90 billion and non-GAAP EPS $3.10 to $3.40

The filing

CompanyGlobus Medical (GMED)
Form8-K, current report
Filed with the SECFeb 20, 2025, 4:20 PM ET
Accession number0001562762-25-000024

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 20, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.